Zoetis Inc.: Business Overview, Financials & Competitive Analysis
Zoetis Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Established market leader with solid 2026 guidance and pipeline momentum, but navigating OA product safety concerns and consumer spending pressures in companion animals. Zoetis demonstrates robust fundamentals with 6% organic revenue growth, strong 43.8% EBITDA margins, and commanding market leadership. However, recent regulatory scrutiny on monoclonal antibody products, macroeconomic pressure.
What is Zoetis Inc.'s industry? Zoetis Inc. (zoetis.com) operates in Animal Health / Veterinary Pharmaceuticals & Biologics. AskCyborg classifies Zoetis Inc. under Animal Health / Veterinary Pharmaceuticals & Biologics in its company registry.
Zoetis Inc. is the global leader in animal health, developing medicines, vaccines, diagnostics, and technologies for companion animals and livestock. With a diversified portfolio spanning 68% companion animals (dogs, ...
Cyborg Score thesis
Established market leader with solid 2026 guidance and pipeline momentum, but navigating OA product safety concerns and consumer...
Read the full analyst-debate transcript →Get the Latest Zoetis Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeZoetis Inc. Overview
Pro stress-test →Zoetis Inc. is the global leader in animal health, developing medicines, vaccines, diagnostics, and technologies for companion animals and livestock. With a diversified portfolio spanning 68% companion animals (dogs, cats, horses) and 31% livestock (cattle, swine, poultry, fish, sheep), the company serves veterinarians, livestock producers, and pet owners worldwide.
Strategic Profile
Pro stress-test →Zoetis employs a "Continuum of Care" strategy—Predict, Prevent, Detect, and Treat—to capture revenue across an animal's entire lifecycle through genetic testing, vaccines, diagnostics, and therapeutics. The company maintains a dominant market position fortified by strong R&D innovation, with a 12-candidate blockbuster pipeline targeting high-value therapeutic areas including chronic kidney disease and oncology.
Competitive Landscape
Pro stress-test →Zoetis competes against IDEXX Laboratories in diagnostics and companion animal care, and Elanco Animal Health in livestock and parasiticides. The company differentiates through its comprehensive portfolio spanning species and channels, plus superior R&D pipeline depth. While Elanco faces pricing headwinds, Zoetis maintains premium positioning supported by 72% gross margins and innovation velocity.
Industry Context
Zoetis Inc. operates in Animal Health / Veterinary Pharmaceuticals & Biologics.
Key facts
Founded: 1950 · Headquarters: Parsippany, New Jersey, US · Revenue: $9.5B · Market cap: $56.8B